Contrarian upgrade from a low-accuracy firm ahead of earnings adds noise, not signal. Wait for post-earnings clarity given mixed institutional flows and declining EPS revisions. The $225 PT is aggressive relative to fundamentals unless guidance surges.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $190.12entry
- T+1 · 7mo ago −1.20%α −0.81% · $187.84
- T+5 · 7mo ago +0.14%α +0.09% · $190.39
- T+20 · 6mo ago +0.23%α −2.93% · $190.56
- T+60 · 4mo ago +9.89%α +4.33% · $208.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
UBS double upgraded NVDA from Neutral to Buy with a new $225 PT, representing 21% upside from current levels. The move follows Wells Fargo and Piper Sandler upgrades in the past two weeks. Consensus remains mixed with only 40% Buy-rated (20/50), below average conviction. UBS’s accuracy is 50% (1/2), below peer median of 55%. Analyst momentum is positive: 3 upgrades in 30 days, 0 downgrades. EPS estimates are trending down over 30 days: -2 net revisions. Institutional activity shows divergence, FMR doubled down while Renaissance trimmed -58.6%. Earnings due in 7 days. Contrarian call from low-accuracy firm ahead of event limits conviction.
Impact Score
Consensus & Targets
Of 50 total analysts, 20 rate Buy/Strong Buy (40%), 22 Hold (44%), 2 Sell/Strong Sell (4%). Consensus is below average in bullishness compared to sector median of 52% Buy ratings. Directionally, consensus is shifting slightly positive with 3 upgrades in the last 30 days and no downgrades.
Consensus price target is $209.36 (mean), $206.50 (median), with a high of $275 and low of $150. Current price is $185.95, implying 12.5% upside to mean. UBS’s $225 PT is 7.2% above the mean and 9.1% above median, placing it in the top quartile of targets. Prior UBS PT was $185, now 21.6% higher.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-22 | UBS | upgrade | Buy | $225.00 |
| 2026-04-20 | Wells Fargo | upgrade | Overweight | $250.00 |
| 2026-04-14 | Piper Sandler | upgrade | Overweight | $214.00 |
| 2026-04-13 | Citigroup | maintain | Neutral | $190.00 |
| 2026-04-13 | Truist Securities | maintain | Hold | $189.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $200.00 |
| 2026-04-02 | HC Wainwright & Co. | maintain | Buy | $237.00 |
| 2026-04-01 | Canaccord Genuity | maintain | Buy | $245.00 |
| 2026-04-01 | Oppenheimer | maintain | Outperform | $275.00 |
| 2026-03-17 | HSBC | maintain | Reduce | $150.00 |
In the past 30 days, 3 analysts upgraded NVDA, 0 downgraded. EPS revisions show negative momentum: over 30 days, +1 up, -3 down for current quarter; +3 up, -3 down for next year. Current quarter EPS estimate has declined from $3.04 to $3.01, suggesting weakening near-term expectations despite stock upgrades.
Firm Track Record: UBS
UBS accuracy: 55% on 5083 calls | avg return: 4.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 13% | top tier |
| Morgan Stanley | 83% | 5/6 | 5.5% | top tier |
| Piper Sandler | 71% | 5/7 | 1.6% | top tier |
| Wedbush | 67% | 4/6 | 2.1% | top tier |
| JP Morgan | 67% | 2/3 | 2.5% | top tier |
| HC Wainwright & Co. | 57% | 4/7 | 1.4% | above average |
| UBS | 50% | 1/2 | 0.6% | below average |
| Barclays | 50% | 2/4 | -2.8% | below average |
| Canaccord Genuity | 50% | 1/2 | -2.1% | below average |
| Goldman Sachs | 50% | 1/2 | -0.1% | below average |
UBS has a 50% accuracy rate (1 correct out of 2 rated calls) with an average return of +0.6%, ranking below average among 15 covering firms. The median firm accuracy is 55% (2,806/5,083). Top performers include Jefferies (100%, 2/2) and Morgan Stanley (83%, 5/6). UBS’s track record adds limited weight to this call.
Earnings Estimates
Next earnings: Apr 29, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $4.36 | $3.95 to $5.04 | $2.4B | ↑1 ↓0 |
| +1y | $15.83 | $14.34 to $17.60 | $9.3B | ↑2 ↓0 |
| 0q | $3.01 | $1.66 to $4.68 | $2.3B | ↑1 ↓0 |
| 0y | $15.58 | $14.02 to $16.33 | $9.5B | ↑1 ↓0 |
Cross-Platform Signals
Institutional activity is split: FMR LLC doubled position (+632%), Norges Bank initiated new $464M stake, and UBS Group added +35.1%. But Renaissance Technologies cut -58.6% and Wells Fargo & Co. trimmed -32.3%. No insider trades reported. Congressional buys: one small buy by Rep. Cisneros ($1K–$15K). Short interest is elevated at 59.0% short ratio, indicating high bearish positioning ahead of earnings.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers